1. Home
  2. LSTA vs NTWK Comparison

LSTA vs NTWK Comparison

Compare LSTA & NTWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSTA
  • NTWK
  • Stock Information
  • Founded
  • LSTA 1980
  • NTWK 1997
  • Country
  • LSTA United States
  • NTWK United States
  • Employees
  • LSTA N/A
  • NTWK N/A
  • Industry
  • LSTA Misc Health and Biotechnology Services
  • NTWK Computer Software: Prepackaged Software
  • Sector
  • LSTA Health Care
  • NTWK Technology
  • Exchange
  • LSTA Nasdaq
  • NTWK Nasdaq
  • Market Cap
  • LSTA 20.0M
  • NTWK N/A
  • IPO Year
  • LSTA N/A
  • NTWK 1998
  • Fundamental
  • Price
  • LSTA $2.32
  • NTWK $2.35
  • Analyst Decision
  • LSTA Strong Buy
  • NTWK
  • Analyst Count
  • LSTA 1
  • NTWK 0
  • Target Price
  • LSTA $15.00
  • NTWK N/A
  • AVG Volume (30 Days)
  • LSTA 17.8K
  • NTWK 27.2K
  • Earning Date
  • LSTA 05-08-2025
  • NTWK 05-08-2025
  • Dividend Yield
  • LSTA N/A
  • NTWK N/A
  • EPS Growth
  • LSTA N/A
  • NTWK N/A
  • EPS
  • LSTA N/A
  • NTWK N/A
  • Revenue
  • LSTA $1,000,000.00
  • NTWK $62,048,128.00
  • Revenue This Year
  • LSTA N/A
  • NTWK N/A
  • Revenue Next Year
  • LSTA N/A
  • NTWK N/A
  • P/E Ratio
  • LSTA N/A
  • NTWK N/A
  • Revenue Growth
  • LSTA N/A
  • NTWK 9.28
  • 52 Week Low
  • LSTA $2.05
  • NTWK $2.28
  • 52 Week High
  • LSTA $4.20
  • NTWK $3.34
  • Technical
  • Relative Strength Index (RSI)
  • LSTA 42.12
  • NTWK 33.97
  • Support Level
  • LSTA $2.07
  • NTWK $2.33
  • Resistance Level
  • LSTA $2.62
  • NTWK $2.54
  • Average True Range (ATR)
  • LSTA 0.21
  • NTWK 0.11
  • MACD
  • LSTA 0.01
  • NTWK -0.01
  • Stochastic Oscillator
  • LSTA 47.37
  • NTWK 9.09

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

Share on Social Networks: